MedDataX Logo

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

NCT ID: NCT01474083

Last Updated: 2013-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

248 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to study the drug levels and biomarkers in the body and the safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the study will receive placebo for 1 week followed by 1 of 4 treatments for 6 weeks. One of the 4 treatments will be placebo, which does not contain an active ingredient. The study participation includes in-patient and out-patient days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

NCT00366379

Diabetes Mellitus Type 2
COMPLETED PHASE2

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

NCT00924053

Diabetes Mellitus Type 2
COMPLETED PHASE1

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

NCT00266240

Diabetes Mellitus Type 2
COMPLETED PHASE2

A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1

NCT00239187

Type 2 Diabetes
COMPLETED PHASE1

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

NCT01978613

Diabetes Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GK1-399, low dose

Group Type EXPERIMENTAL

GK1-399 (formerly TTP399)

Intervention Type DRUG

Treatment A: GK1-399 200 mg. Oral administration, twice per day.

GK1-399, high dose, once per day

Group Type EXPERIMENTAL

GK1-399 (formerly TTP399)

Intervention Type DRUG

Treatment B: GK1-399 800 mg. Oral administration, once per day.

GK1-399, high dose, twice per day

Group Type EXPERIMENTAL

GK1-399 (formerly TTP399)

Intervention Type DRUG

Treatment C: GK1-399 800 mg. Oral administration, twice per day.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Dose-matched placebo. Oral administration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GK1-399 (formerly TTP399)

Treatment A: GK1-399 200 mg. Oral administration, twice per day.

Intervention Type DRUG

GK1-399 (formerly TTP399)

Treatment B: GK1-399 800 mg. Oral administration, once per day.

Intervention Type DRUG

GK1-399 (formerly TTP399)

Treatment C: GK1-399 800 mg. Oral administration, twice per day.

Intervention Type DRUG

Placebo

Dose-matched placebo. Oral administration.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be male or female, aged 18 through 75 years at screening.
* Have a diagnosis of Type 2 Diabetes Mellitus (T2DM)
* On a stable dose of background medication for the treatment of diabetes
* Body Mass Index (BMI) between 20-40 kg/m2 (inclusive)

Exclusion Criteria

* Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

vTv Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aaron Burstein, Pharm.D.

Role: STUDY_DIRECTOR

TransTech Pharma, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Forest Investigative Site 009

Little Rock, Arkansas, United States

Site Status

Forest Investigative Site 006

Chula Vista, California, United States

Site Status

Forest Investigative Site 002

DeLand, Florida, United States

Site Status

Forest Investigative Site 001

Miami, Florida, United States

Site Status

Forest Investigative Site 010

Overland Park, Kansas, United States

Site Status

Forest Investigative site 011

Saint Paul, Minnesota, United States

Site Status

Forest Investigative Site 005

Springfield, Missouri, United States

Site Status

Forest Investigative Site 003

Neptune City, New Jersey, United States

Site Status

Forest Investigative Site 008

Willingboro, New Jersey, United States

Site Status

Forest Investigative Site 007

New York, New York, United States

Site Status

Forest Investigative Site 004

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GK1-MS-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
NCT02653599 COMPLETED PHASE2
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers
NCT00501930 COMPLETED PHASE1
Study In People With Type 2 Diabetes
NCT00196989 COMPLETED PHASE2
Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects
NCT01690169 COMPLETED PHASE1
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
NCT00859755 COMPLETED PHASE1
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
NCT02211261 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
NCT01407003 COMPLETED PHASE1/PHASE2
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
NCT04465877 COMPLETED PHASE1
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers
NCT00933062 COMPLETED PHASE1
Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.
NCT00759720 TERMINATED PHASE3
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)
NCT01971554 COMPLETED PHASE1
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
NCT05478525 COMPLETED PHASE2
First-in-Human Single Ascending and Multiple Dose of GLPG0259
NCT00905138 COMPLETED PHASE1
To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes
NCT01176097 COMPLETED PHASE1
Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
NCT01915849 COMPLETED PHASE1/PHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.
NCT01607385 COMPLETED PHASE1
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
NCT01789788 COMPLETED PHASE1
A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers
NCT01545570 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
NCT02445911 COMPLETED PHASE1
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
NCT00743002 COMPLETED PHASE2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes
NCT02212925 TERMINATED PHASE1
A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.
NCT00437606 TERMINATED PHASE1
Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
NCT00949091 COMPLETED PHASE1
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
NCT00495469 COMPLETED PHASE2
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
NCT05890950 COMPLETED PHASE1